Overview

Survodutide (development code BI 456906) is an investigational long-acting peptide co-agonist targeting both the glucagon receptor (GCGR) and the glucagon-like-peptide-1 receptor (GLP-1R). It is being co-developed by Boehringer Ingelheim and Zealand Pharma and, as of this writing, is in Phase 3 trials for obesity and for metabolic-dysfunction-associated steatohepatitis (MASH). It has not received regulatory approval in any jurisdiction.

Survodutide sits in the same broader class as Tirzepatide — a GLP-1/GIP dual agonist — and Retatrutide — a GLP-1/GIP/glucagon triagonist. Where those compounds engage the GIP receptor, survodutide’s second pharmacology is glucagon-receptor agonism, which is hypothesised to add a direct thermogenic and hepatic-lipid-clearing component to GLP-1-mediated appetite suppression.

Publicly disclosed material characterises survodutide as a lipidated 29-residue peptide backbone with fatty-acid tethering to extend albumin-binding half-life, similar in design principle to Semaglutide, but with a co-agonist activity profile. The exact sequence has not been fully disclosed in the peer-reviewed literature reviewed for this entry.

Mechanism (as reported in the literature)

  • GLP-1-receptor agonism. Contributes appetite-suppressive and glycaemic effects consistent with the GLP-1 class, including delayed gastric emptying and enhanced glucose-dependent insulin secretion.
  • Glucagon-receptor agonism. Reported to increase hepatic fatty-acid oxidation and to raise energy expenditure. Adding glucagon activity is a strategy to accelerate fat loss beyond what GLP-1 monoagonism achieves — while accepting the requirement to titrate carefully because glucagon-receptor activation can raise hepatic glucose output.
  • Balanced potency. Preclinical characterisations describe survodutide as retaining meaningful glucagon-receptor activity at doses that also fully engage GLP-1 receptors.
  • Long half-life. Fatty-acid-mediated albumin binding is described as supporting once-weekly subcutaneous administration.

Research findings

  • Phase 2 obesity trial (Le Roux et al., 2024). A randomised, double-blind, placebo-controlled trial reported mean body-weight reductions up to approximately 19% at 46 weeks at the highest survodutide dose, compared with roughly 2% in the placebo arm. Published in The Lancet, 2024;403(10432):1266–1275.
  • Phase 2 MASH trial (Sanyal et al., 2024, NEJM). In biopsy-confirmed MASH, survodutide reported significant reductions in histological MASH activity relative to placebo over a 48-week interval, alongside reductions in liver fat fraction on MRI-PDFF.
  • Type-2 diabetes cohorts. Earlier Phase 2 work in type-2 diabetes reported reductions in HbA1c and body weight, with the diarrhoea-and-nausea profile characteristic of GLP-1 titration.
  • Titration and tolerability. Across the published trials, dose escalation over multiple weeks was reported to be necessary to manage nausea, vomiting, and diarrhoea — mirroring the wider GLP-1 class — with additional attention to fasting glucose because of the glucagon-agonist component.

Common dosing (from published research protocols)

The Phase 2 obesity programme used weekly subcutaneous doses that escalated from 0.6 mg up to 4.8 mg over multiple weeks. The reported typical range therefore spans 600 to 4,800 mcg weekly, with the upper end producing the largest weight-loss effect and the greatest incidence of gastrointestinal adverse events. These are ranges reported in the published trial literature, not recommendations.

Reconstitution

Reconstitution practice for research-grade lyophilised survodutide has not been described in a formal clinical publication and depends on vial strength. A 5 mg vial reconstituted with 2 mL bacteriostatic water yields a 2,500 mcg/mL solution.

  • 600 mcg = 0.24 mL = 24 units on a U-100 syringe
  • 2,400 mcg = 0.96 mL = 96 units
  • 4,800 mcg = 1.92 mL — more conveniently reconstituted at a higher concentration (e.g., 5 mg in 1 mL → 5,000 mcg/mL) if the higher dose is being modelled

Storage

Lyophilised survodutide is reported as stable refrigerated. Once reconstituted, storage practice reported in the wider peptide-research literature is refrigeration at 2–8 °C with freezer storage for long-term stability.

  • Semaglutide — GLP-1 monoagonist; a useful contrast for potency at the GLP-1 receptor alone.
  • Tirzepatide — GLP-1/GIP dual agonist.
  • Retatrutide — GLP-1/GIP/glucagon triagonist; adds GIP activity to survodutide’s mechanism.

Common stacks

References

  • Le Roux, C. W., et al. (2024). “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet, 403(10432), 1266–1275.
  • Sanyal, A. J., et al. (2024). “A phase 2 randomized trial of survodutide in MASH and fibrosis.” New England Journal of Medicine, 391(4), 311–319.
  • Boehringer Ingelheim / Zealand Pharma (2023–2024). Publicly disclosed materials on BI 456906 mechanism and phase 2 programme.